<?xml version="1.0" encoding="UTF-8"?>
<p>These dual AChE/BACE-1 inhibitors confirmed once again the importance of these enzymes in the pathology of AD and how the combined action against them still represent a valuable approach to address cognitive impairment and A
 <italic>Î²</italic>-related dysfunctions.
</p>
